You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 8,450,311


✉ Email this page to a colleague

« Back to Dashboard


Title:Pharmaceutical compositions containing a fluoroquinolone antibiotic drug
Abstract: Pharmaceutical compositions containing a fluoroquinolone antibiotic drug are disclosed. The compositions exhibit improved homogeneity, improved bioavailability, lower turbidity or a combination thereof. The composition can be use as otic or nasal compositions, but are particularly useful as ophthalmic compositions.
Inventor(s): Campins; Inmaculada (Mataro, ES), Jimenez; Nuria (Barcelona, ES), Vidal; Roman (Vallromanes, ES), Carreras; Nuria (Caldes de Montbui, ES), Martinez; Carmen (Llica de Vall, ES), Galan; Francisco Javier (Teia, ES)
Assignee: Novartis AG (Basel, CH)
Filing Date:May 29, 2009
Application Number:12/474,307
Claims:1. An aqueous pharmaceutical composition, comprising: a fluoroquinolone drug consisting of moxifloxacin in the composition at a concentration that is at least 0.4 w/v % but less than 1.0 w/v %; and a pharmaceutical vehicle for the fluoroquinolone drug, the pharmaceutical vehicle consisting essentially of: i. sodium chloride in an amount that provides a weight/volume ratio of sodium chloride to the fluoroquinolone drug in the composition that is between 1.0 and 1.7; ii. a surfactant that assists in evenly distributing the fluoroquinolone drug throughout the pharmaceutical vehicle wherein the surfactant is a polyether alcohol; iii. a borate and a polyol; iv. a polysaccharide viscosity enhancing agent comprised of xanthan gum in an amount such that the concentration of the xanthan gum in the composition is at least 0.3 w/v % but less than 1.2 w/v % wherein the xanthan gum is at least 90% by weight of the viscosity enhancing agent; v. a pH adjusting agent; and vi. water; wherein the composition is an aqueous ophthalmic solution and wherein the composition exhibits turbidity that is less than 13 NTU.

2. A composition as in claim 1 wherein the composition is located within a container that dispenses the composition as drops.

3. A composition as in claim 1 wherein the sodium chloride is in the composition at a concentration such that the weight/volume ratio of sodium chloride to the fluoroquinolone drug that is between 1.1 and 1.4.

4. A composition as in claim 1 wherein the polyol comprises sorbitol.

5. A composition as in claim 1 wherein the viscosity enhancing agent consists of xanthan gum.

6. A composition as in claim 1 wherein the pharmaceutical vehicle consists essentially of sodium chloride, a surfactant, a borate, a polyol, xanthan gum, sodium hydroxide and water.

7. A composition as in claim 1 wherein the composition has a pH of 6.8 to 7.4 and the turbidity is less than 10 NTU.

8. An aqueous pharmaceutical composition, comprising: a fluoroquinolone drug wherein the fluoroquinolone drug is moxifloxacin at a concentration that is at least 0.4 w/v % but less than 1.0 w/v %; and a pharmaceutical vehicle for the fluoroquinolone drug, the pharmaceutical vehicle consisting essentially of: i. sodium chloride in an amount that provides a weight/volume ratio of sodium chloride to the fluoroquinolone drug in the composition that is between 1.1 and 1.4; ii. a surfactant that assists in evenly distributing the fluoroquinolone drug throughout the pharmaceutical vehicle; iii. a borate and a polyol; and iv. a polysaccharide viscosity enhancing agent comprised of xanthan gum in an amount such that the concentration of the xanthan gum in the composition is at least 0.3 w/v % but is less than 1.2 w/v % wherein the xanthan gum is at least 90% by weight of the viscosity enhancing agent; v, a pH adjusting agent; and vi, water; wherein the composition is an aqueous ophthalmic solution and wherein the composition is located within a container that dispenses the composition as drops and wherein the composition exhibits turbidity that is less than 10 NTU.

9. A composition as in claim 8 wherein the composition has a pH of 6.8 to 7.4.

10. A composition as in claim 8 wherein the polysaccharide viscosity enhancing agent consists of xanthan gum.

11. A composition as in claim 8 wherein the surfactant is a polyether alcohol.

12. A composition as in claim 8 wherein the surfactant is an alkyl aryl polyether alcohol.

13. A composition as in claim 12 wherein the polysaccharide viscosity enhancing agent consists of xanthan gum.

14. A composition as in claim 12 wherein the composition has a pH of 6.8 to 7.4.

15. A composition as in claim 1 wherein the surfactant is an alkyl aryl polyether alcohol.

16. An aqueous pharmaceutical composition, comprising: a fluoroquinolone drug comprised of moxifloxacin in the composition at a concentration that is at least 0.4 w/v % but less than 0.7 w/v %; and a pharmaceutical vehicle for the fluoroquinolone drug, the pharmaceutical vehicle including the following: i. sodium chloride in an amount that provides a weight/volume ratio of sodium chloride to the fluoroquinolone drug in the composition that is between 1.1 and 1.4; ii. a surfactant that assists in evenly distributing the fluoroquinolone drug throughout the pharmaceutical vehicle wherein the surfactant is a polyether alcohol; iii. a borate and a polyol; iv. a polysaccharide viscosity enhancing agent comprised of xanthan gum in an amount such that the concentration of the xanthan gum in the composition is at least 0.6 w/v % but is less than 0.75 w/v % wherein the xanthan gum is at least 90% by weight of the viscosity enhancing agent; v. a pH adjusting agent; and vi. water; wherein the composition is an aqueous ophthalmic solution and wherein the composition exhibits turbidity that is less than 13 NTU.

17. A composition as in claim 16 wherein the composition has a pH of 6.8 to 7.4 and the turbidity is less than 10 NTU.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.